I’ve been watching the big drug distributors for years, and something about this one keeps catching my attention. After a stretch of market swings that left plenty of investors reaching for the antacid, one name has quietly put together a solid climb of more than 30 percent so far in 2026. The curious part is that the valuation still looks reasonable. That combination of progress and remaining upside is rare enough that it deserves a closer look.
The Quiet Shift Turning a Traditional Wholesaler Into Something More
Most people still think of this company as the giant that moves boxes of pills from manufacturers to pharmacies and hospitals. That description was accurate for a long time. The business ran on razor-thin spreads and volume. Yet the mix inside the company has been changing, and the latest quarterly numbers made that shift hard to ignore.
The higher-margin pieces—oncology support, specialty services, and prescription technology—are no longer just nice add-ons. They are starting to pull a much larger share of the profit. In the most recent quarter those units delivered roughly 15 percent of revenue but nearly 37 percent of adjusted segment operating profit. That kind of leverage is exactly what management has been aiming for.
I find the numbers almost surprising every time I revisit them. The traditional wholesale side still generates the bulk of sales, around 82 percent in the latest period, yet it contributed only about half of the adjusted operating profit. Its margin did improve a bit, rising 16 basis points to 1.14 percent thanks to better operating leverage. Still, the real story sits elsewhere.
Oncology and Multispecialty: The Growth Engine
Community cancer care has been moving out of big hospital settings for years. This company positioned itself early to support independent oncology practices. That unit now accounts for about 13.5 percent of revenue and more than 21 percent of adjusted segment operating profit, carrying a 2.85 percent margin. Operating profit rose 8 percent on the surface, but once you strip out some one-time gains from the year-ago period the underlying growth looked closer to 23 percent. That is the kind of trajectory that changes the overall earnings profile.
Demand drivers feel durable. An aging population, rising prescription volumes, and a pipeline full of complex specialty medicines all point in the same direction. Cancer treatments in particular are increasingly handled in community clinics rather than large academic centers. Providers want reliable partners that can handle the logistics, the data, and the patient support that come with those therapies. Scale and regulatory know-how create real barriers, which is why only a handful of players dominate national distribution.
I’ve noticed that this particular wholesaler has leaned harder into oncology and biopharma services than some of its peers. That focus is starting to show up in the numbers.
Prescription Technology: Small Revenue, Outsized Profit
The technology side remains the quiet standout. It helps manufacturers get patients onto therapy and stay on it. In the latest quarter it represented only 1.4 percent of total revenue yet delivered more than 15 percent of adjusted segment operating profit. The margin sat near 20 percent, and operating profit grew 18 percent while the margin itself expanded by more than a full percentage point.
Those economics are hard to ignore. Once a technology platform is built and scaled, incremental revenue tends to fall to the bottom line more efficiently than pure distribution volume. Management keeps investing in automation and artificial intelligence across the broader network, which should support further productivity gains.
Portfolio Moves That Accelerate the Transition
Recent deals and planned separations are designed to push the mix even further toward higher-growth, higher-margin work. The company closed the acquisition of a clinical research and commercialization services provider in early November. That business is expected to contribute a modest 10 to 20 cents per share this year and potentially $1.60 to $1.80 by year three. The addition fits the broader specialty strategy.
Around the same time, the company announced a sizable investment alongside a private-equity partner for a near-half stake in the largest independent provider of home and alternate-site infusion services. The deal values that business at roughly $5.8 billion and should close in the first half of 2027. The chief executive has been clear that the company likes the trajectory of community and home-based care and sees this as a way to incubate future platforms.
Then there is the planned separation of the medical-surgical unit. That business supplies physician offices and nursing homes. It will be renamed and is expected to go public in the second half of 2027. Management has already signaled that full-year segment profit for the unit could range from a modest decline to flat, which helps explain the desire to spin it out. Removing a slower-growing piece should leave the remaining company with a cleaner growth profile.
One more piece of visibility arrived with an agreement in principle to extend the long-standing pharmaceutical distribution partnership with a major retail pharmacy chain through mid-2032. Once finalized, that contract removes a potential overhang and gives clearer line of sight into a key customer relationship.
Earnings Guidance Keeps Moving Higher
The second-quarter report brought another upward revision. Fiscal 2027 adjusted earnings guidance now sits in a range of $45.60 to $46.40 per share, up from the prior $44.20 to $45.00. That implies growth of 17 to 19 percent. The raise reflected strength across the portfolio rather than a one-off boost.
Cash generation has been equally solid. Free cash flow reached about $2.9 billion in the second quarter alone, bringing the first-half total to $2.6 billion—more than double the year-ago figure even after a seasonally soft first quarter. Full-year free cash flow is expected between $4.5 billion and $4.9 billion. At the current market value that implies a free-cash-flow yield near 3.8 percent.
Capital returns remain aggressive. Roughly $3.4 billion of stock was bought back in the first half, and the company expects to repurchase about $5 billion for the full fiscal year. A 15 percent dividend increase earlier in the year adds another layer of shareholder return. Those buybacks amplify per-share growth as the earnings base expands.
When you combine broad-based volume growth with operational excellence and productivity, the operating leverage becomes meaningful.
That sentiment from the finance leadership matches what the numbers are showing. Prescription volumes, specialty products, and certain high-demand therapies all contributed. Management noted that demand for one particular class of therapies is beginning to normalize after a strong initial uptake, which is worth watching but does not appear to be derailing the overall picture.
Valuation Still Leaves Room
After the recent rally the shares trade around 23 times the midpoint of the new fiscal 2027 guidance. That remains below the roughly 25.3 times five-year median multiple. Some will argue the historical median no longer fits because the business is becoming more dynamic and faster growing. Others will point to higher interest rates as a reason multiples should compress. Those two forces largely offset each other in my view.
Applying the longer-term median multiple to consensus calendar 2027 earnings estimates produces a price target in the neighborhood of $1,278, or roughly 19 percent above recent levels. Continued guidance increases and successful integration of the new specialty assets could support further multiple expansion. The stock does trade at a premium to one of its main peers, so execution has to stay clean.
I’ve found that markets sometimes lag when a company is in the middle of a genuine mix shift. Investors keep applying the old wholesale multiple even as the profit contribution from higher-margin work keeps rising. That gap can close over time if the company delivers.
Risks That Deserve Attention
No investment story is complete without the other side of the ledger. Regulatory changes to certain government programs could pressure distributor margins. The largest customer relationship is still subject to final documentation on the long-term extension. Legacy liabilities related to past opioid distribution remain on the books. Execution risk around the new investments and the planned separation is real. Pricing and coverage shifts in high-volume therapy classes can also affect volumes and margins, even if the absolute contribution remains meaningful.
These are not theoretical concerns. They need to be monitored. At the same time, the company’s scale, compliance infrastructure, and growing specialty footprint provide some natural defenses that smaller players lack.
What the Numbers Suggest About Quality of Earnings
Looking across the segments paints a clearer picture of how the earnings base is evolving. The legacy wholesale business still delivers the volume and the relationships. Its modest margin expansion shows that operational discipline continues. The oncology and multispecialty unit brings faster growth and better profitability. The technology platform contributes high-margin, sticky revenue that scales efficiently. Together they are lifting the overall quality of the profit stream.
Free cash flow conversion has been strong enough to fund both substantial buybacks and strategic investments without stretching the balance sheet. That flexibility matters when opportunities appear in specialty care or technology. The planned separation of the slower medical-surgical piece should further concentrate the remaining earnings on the higher-growth areas.
Perhaps the most interesting aspect is how little the market seems to have fully priced the durability of this shift. Guidance has been raised, margins in the growth segments are expanding, and the portfolio actions are concrete rather than conceptual. Yet the multiple still sits below the longer-term average. That gap is what keeps the stock on my watch list.
Broader Industry Tailwinds Supporting the Strategy
Several structural trends continue to favor a scaled distributor that has invested in specialty capabilities. Specialty medicines account for a rising share of total drug spending. Many of those therapies require temperature control, complex reimbursement support, and patient-assistance programs. Manufacturers increasingly outsource the patient-access work. Providers look for partners that can guarantee supply security and handle the regulatory complexity of controlled substances.
Home and alternate-site infusion is another area seeing steady growth as care moves closer to the patient. The investment in that space aligns with the same theme. Community oncology practices need efficient partners for both product and services. All of these trends play to the strengths of a company that already operates a national network and has spent years building the supporting technology and clinical capabilities.
In my experience, these kinds of multi-year mix shifts rarely show up fully in a single quarter. They accumulate. The latest results feel like another confirmation that the accumulation is underway.
Capital Allocation and Shareholder Returns
The combination of rising free cash flow and disciplined capital returns is underappreciated. Buying back stock at a time when the business is improving its growth profile can be powerful. The planned $5 billion of repurchases this fiscal year, on top of the dividend increase, supports per-share earnings growth even if top-line expansion is moderate. The cash flow outlook also leaves room for further bolt-on investments in specialty or technology without jeopardizing the return of capital.
Management has shown a willingness to reshape the portfolio when pieces no longer fit the higher-growth vision. The medical-surgical separation is the latest example. That approach tends to keep the remaining company focused and more valuable over time.
Putting the Valuation in Context
Twenty-three times forward earnings is not cheap in an absolute sense. Relative to the company’s own history and relative to the improving growth and margin profile, it still looks reasonable. The free-cash-flow yield near 4 percent provides a floor of sorts. If the company continues to raise guidance as the specialty platforms mature, the multiple could expand toward or beyond the historical median without requiring heroic assumptions.
Of course multiples can compress if interest rates move higher or if sector sentiment turns. That risk is real. Yet the earnings trajectory itself appears more durable than it did a few years ago when the business was more heavily weighted toward pure wholesale.
I keep coming back to the simple observation that the profit mix is changing faster than many models seem to assume. That is usually a constructive setup for patient investors.
What to Watch in the Coming Quarters
Several milestones will matter. Finalization of the extended distribution agreement with the large retail customer would remove uncertainty. Closing of the infusion investment in 2027 would add another growth platform. Progress on the medical-surgical separation and eventual public listing would clarify the remaining earnings base. Integration of the recently acquired clinical services business and its contribution to earnings will also be tracked closely.
On the organic side, investors will watch whether the oncology and technology margins continue to expand and whether the traditional wholesale business can maintain its recent operating leverage. Any signs of broader prescription volume softness or sudden shifts in high-volume therapy classes would need to be evaluated in context of the overall mix.
The company has already demonstrated an ability to raise the earnings outlook while investing for the future. Sustaining that balance is the next test.
A Business That No Longer Fits Its Old Label
At this point it feels increasingly inaccurate to describe the company simply as a drug wholesaler. The label still fits the largest piece of revenue, yet it understates the contribution of higher-margin services and technology. Growing oncology support, infusion capabilities, and prescription technology platforms are improving both the growth rate and the quality of earnings. Substantial share repurchases are amplifying the per-share impact of that improvement.
The stock has already delivered a strong move this year. That fact alone makes some investors cautious. Yet the valuation relative to history and relative to the evolving earnings power still leaves room. Management continues to raise the bar on guidance while reshaping the portfolio toward faster-growing, more profitable work.
I’ve followed enough of these multi-year transitions to know they are rarely linear. There will be quarters that look less impressive. Regulatory or customer news can create short-term noise. Still, the direction of travel appears clear. The company is becoming a broader healthcare services and technology platform with a strong distribution backbone rather than a pure volume-driven wholesaler.
For investors who prefer businesses that compound through a combination of operational improvement, strategic repositioning, and disciplined capital return, the story remains compelling. The recent results and portfolio actions reinforce that view. Whether the market fully recognizes the durability of the shift in the near term is another question. History suggests that recognition often arrives gradually, which can leave an opportunity for those willing to look past the traditional label.
The next few quarters will test whether the momentum can be sustained as investment in both core distribution capabilities and specialty platforms continues. So far the evidence points in a constructive direction. That combination of improving fundamentals and a valuation that has not fully caught up is what keeps the name interesting even after a sizable rally.
In the end, the transformation is less about dramatic overnight change and more about steady accumulation of higher-quality earnings. Those kinds of stories can be easy to underestimate until the numbers make the progress obvious. The latest quarter provided another data point that the progress is real. For patient capital, that may be enough to stay engaged.
